Dynamic Hyperinflation and Tiotropium

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gelb, Arthur F., M.D.
• Collaborators: Boehringer Ingelheim; Pfizer
• Treatments: Tiotropium Bromide

Criteria

Inclusion Criteria:

• Moderately severe COPD patients age 40-85 yr with post 180ug albuterol FEV 1 between 60 and 79% predicted and FEV 1/FVC < 70%.

• Smoking history > 10 pack yr.

• Clinically stable X 6 weeks.

• No oxygen usage.

Exclusion Criteria:

• History of asthma

• Clinically unstable

• Any other significant medical problem precluding full cooperation for study